Artivion, Inc. (NYSE:AORT) SVP Sells $253,692.00 in Stock

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean F. Holloway sold 8,748 shares of the stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $29.00, for a total transaction of $253,692.00. Following the sale, the senior vice president now owns 178,510 shares of the company's stock, valued at approximately $5,176,790. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Artivion Trading Down 0.4%

Shares of NYSE AORT traded down $0.13 during trading on Friday, hitting $29.58. 463,268 shares of the company traded hands, compared to its average volume of 328,681. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $1.26 billion, a P/E ratio of -1,479.00 and a beta of 1.54. The company has a 50-day moving average price of $25.52 and a 200-day moving average price of $27.37. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $32.33.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $98.98 million during the quarter, compared to analysts' expectations of $94.81 million. On average, equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Institutional investors have recently bought and sold shares of the business. Diker Management LLC acquired a new position in shares of Artivion during the 1st quarter valued at $369,000. Fred Alger Management LLC purchased a new position in Artivion in the first quarter valued at about $2,969,000. Parkman Healthcare Partners LLC acquired a new position in shares of Artivion during the first quarter worth about $2,744,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company's stock worth $580,000 after purchasing an additional 1,032 shares in the last quarter. Finally, Bridger Management LLC purchased a new stake in shares of Artivion in the first quarter worth about $1,580,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Stifel Nicolaus dropped their price objective on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.